Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Jun 15, 2026
Reporting period
Not applicable
Filed with the SEC
Jun 16, 2026
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001825009-26-000001
Filed / recorded
Jun 16, 2026, 12:18 AM UTC
Added to OQRO
Oct 7, 2026, 5:51 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
LENZ Therapeutics, Inc.
Issuer CIK
1815776
Ticker
LENZ
Reporting person
Frederic Guerard
Relationship
Director
Security
Stock Option (right to buy)
Table
Derivative (Table II)
Transaction date
Jun 15, 2026
Transaction code
A
Shares / units
22,100
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
22,100
Ownership form
Direct
Amendment
No
Footnotes from the filing
Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders.